AIML.CN AI/ML Innovations (CNQ) C$0.035 19 Jan 2026 Market hrs: catalyst needed
AIML.CN stock trades at C$0.035 on the Canadian CNQ exchange as of 19 Jan 2026 during market hours. This small healthcare AI play shows thin liquidity with volume 473,605 and a market cap near C$5,889,240. Fundamentals are weak: EPS is -0.03 and PE is -1.17. Investors in AIML.CN stock should weigh the patent-pending digital health platform against limited revenues and volatile volume. We examine valuation, technicals, sector context, and the catalysts that could move the share price.
AIML.CN stock: intraday snapshot and liquidity
AIML.CN stock opened at C$0.035 and remains at C$0.035 with day low and high equal at C$0.035. Average volume is 380,046 with todays volume at 473,605, giving relative volume 1.25. The 50-day average price is C$0.0388 and the 200-day average is C$0.05818, indicating a downtrend versus medium-term averages.
AIML.CN stock: fundamentals and valuation
AI/ML Innovations Inc. operates in digital healthcare and wearable tech from Victoria, Canada. Revenue per share TTM is 0.00079 while net income per share TTM is -0.03104. Cash per share TTM is 0.00532 and book value per share TTM is 0.00747. Price to sales ratio TTM is 35.00 and price to book is 4.58, reflecting a richly priced microcap relative to its modest revenue. The company reports EPS -0.03 and a negative PE of -1.17, signaling continued losses.
AIML.CN stock: technicals and short-term trading signals
Technicals for AIML.CN stock show neutral to weak momentum. RSI is 40.70, ADX is 14.53 (no trend), and MACD is flat. Bollinger middle band sits at C$0.04 with lower band C$0.03. The 3-month ROC is -12.50%, consistent with the stocks 3-month drop of 30.00%. Traders should expect low liquidity spikes; stop levels should consider the year low C$0.03 and psychological levels at C$0.04 and C$0.05.
AIML.CN stock: sector and market context
AI/ML Innovations is classified in Healthcare, Medical – Healthcare Information Services. The broader healthcare sector shows modest gains YTD while large-cap healthcare names trade at healthier margins. AIML.CN stock lacks scale versus sector averages: average sector ROE is positive while AIML reports ROE -3.31%. Sector performance reduces the likelihood of a sector-driven rerating without company-specific milestones such as pilot wins or regulatory progress.
AIML.CN stock: risks, catalysts and news flow
Key risks include low revenue, negative margins, sparse analyst coverage, and potential dilution. Catalysts that could reprice AIML.CN stock are signed customer contracts, wearable device rollouts, clinical validation, or clearer licensing revenue. Recent comparative mention appears in industry coverage Investing.com comparison note. For real-time quotes and company filings, see our internal page at Meyka AIML.CN page.
Meyka AI grade and forecast for AIML.CN stock
Meyka AI rates AIML.CN with a score out of 100 as C+ (58.20/100) – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of C$0.01710 versus the current C$0.035, implying -51.14% downside. This forecast is model-based and not a guarantee. Investors should treat the grade as part of broader due diligence and not as personalized advice.
Final Thoughts
AIML.CN stock is a thinly traded AI healthcare microcap priced at C$0.035 on the CNQ exchange with clear upside only if company-specific catalysts arrive. Financials show EPS -0.03, negative margins, and a high price-to-sales ratio of 35.00, making valuation reliant on future growth. Technically the stock is out of favor with RSI 40.70 and a 3-month decline of 30.00%. Meyka AI’s forecast model projects C$0.01710 in one year, implying -51.14% versus today; alternative recovery targets could be C$0.04 (short-term) and C$0.10 (optimistic), implying +14.29% and +185.71% respectively. These targets assume successful commercial rollouts or licensing revenue. For active traders, focus on volume spikes, pilot announcements, and any clinical validation. For long-term investors, monitor revenue growth, cash runway, and dilution risk. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model-based projections and not guarantees.
FAQs
What is the current price of AIML.CN stock?
AIML.CN stock trades at C$0.035 on the CNQ exchange as of 19 Jan 2026 during market hours. Day low and high are both C$0.035 with volume 473,605 and average volume 380,046.
What are the main risks for AIML.CN stock?
Main risks include continued negative earnings (EPS -0.03), low revenue, possible dilution, and limited liquidity. The company must deliver clear revenue milestones to justify valuation.
How does Meyka AI rate AIML.CN stock and what is the forecast?
Meyka AI rates AIML.CN C+ (58.20/100) – HOLD. Meyka AI’s forecast model projects C$0.01710 in one year versus current C$0.035, implying about -51.14%. Forecasts are projections and not guarantees.
What catalysts could move AIML.CN stock higher?
Positive catalysts include signed commercial contracts, device rollouts, clinical study results, or licensing deals that convert technology into recurring revenue and reduce dilution risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
